NCT01998841View on ClinicalTrials.gov

A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

PHASE2CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

December 20, 2013

Primary Completion Date

March 22, 2022

Study Completion Date

August 8, 2023

Conditions
Alzheimer's Disease
Interventions
DRUG

Crenezumab

Crenezumab will be administered as per the schedule specified in the treatment arm.

DRUG

Placebo

Placebo will be administered as per the schedule specified in the treatment arm.

Trial Locations (4)

Unknown

Fundacion Cardiomet, Armenia

Clínica de Marly, Bogotá

Grupo Neurociencias de Antioquia, Medellín

Hospital San Juan de Dios, Yarumal

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

Banner Alzheimer's Institute

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

Genentech, Inc.

INDUSTRY